Advertisement

Latest News

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

8 hours ago

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

10 hours ago

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

12 hours ago

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

12 hours ago

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

13 hours ago

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Advertisement
Advertisement